サンプル依頼リスト カート
  • English
  • Korean
表紙：血球貪食性リンパ組織球症治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1374770

血球貪食性リンパ組織球症治療の世界市場-2023年～2030年

Global Hemophagocytic Lymphohistiocytosis Treatment Market -2023-2030

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
血球貪食性リンパ組織球症治療の世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

世界の血球貪食性リンパ組織球症治療市場は、そのダイナミクスに影響を与える様々な要因によって、長年にわたって著しい成長と変貌を遂げてきました。珍しい病気である血球貪食性リンパ組織球症（HLH）は、主に乳幼児が罹患します。この疾患は一般的に小児に受け継がれます。成人は、がんや感染症など様々な病気からHLHを発症する可能性があります。

特に新興経済諸国における政府投資と研究開発は、今後も先進的な製品や技術の利用を促進し、世界の血球貪食性リンパ組織球症治療薬市場を押し上げると思われます。それぞれの革新的製品には、より良い治療のためのモノクローナル抗体などの新規薬剤の使用が含まれます。

市場促進要因：市場抑制要因

主要プレーヤー間の買収とパートナーシップの拡大

新興経済諸国は、高い所得水準、投資、インフラ整備に牽引され、ヘルスケア分野の改善において急速な成長を遂げています。いくつかの国では、血球貪食性リンパ組織球症治療薬の研究成果が高く評価され、大きな需要が生じています。主要企業による様々な買収や製品の発売は、市場の成長を促進する重要な要因です。

2023年3月9日、免疫療法における二重特異性抗体を発明した臨床段階のバイオ医薬品会社であるF-star Therapeutics, Inc.は、Sino Biopharmaceutical Limited（以下、「Sino Biopharm」）の英国に拠点を置く完全子会社であるinvoX Pharma Limitedによる買収に成功し、現金評価総額約1億6,100万米ドル（1株当たり7.12ドル）で買収されました。

Canadian Journal of Health Technologies 2022によると、アナキンラは血球貪食性リンパ組織球症（HLH）患者の28日死亡率および死亡確率を低下させる可能性があり、1件のレトロスペクティブ・コホート研究（1件の包括的レビューに含まれる）のデータによると、アナキンラはHLH患者の28日死亡率および死亡確率を低下させる可能性があります。

さらに、血球貪食性リンパ組織球症の管理に対する新しい技術や薬剤の利用が増加しています。人々の意識の高まりと革新的な製品開発のための研究の増加は、血球貪食性リンパ組織球症治療薬市場の成長を促進する主な要因であろう。

薬物療法に伴う副作用

高血圧、感染症、輸液関連の副作用（発熱、発赤、発疹、発汗）、低血中カリウム、発熱、便秘が代表的な副作用です。発熱、脱力感、咳、呼吸困難、下痢、胃部不快感、悪寒、発汗、排尿時の灼熱感、頻尿は重篤な感染症の症状です。これらは主要な臨床試験で報告された数少ない有害事象です。ガミファント使用者が経験したこれらの追加的な有害事象（全グレード）の10％未満は、嘔吐、急性腎障害、無力症、呼吸困難、徐脈、消化管出血、鼻出血、末梢性浮腫などでした。

本レポートの詳細について- サンプル請求

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 主要プレーヤー間の買収とパートナーシップの拡大
      • 技術的進歩と開発の高まり
    • 抑制要因
      • 投薬に伴う副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • SWOT分析
  • 特許分析
  • ロシア・ウクライナ戦争の影響分析
  • DMI意見

第6章 COVID-19分析

第7章 タイプ別

  • 家族性血球貪食性リンパ組織球症
  • 後天性血球貪食性リンパ組織球症

第8章 薬剤別

  • 抗悪性腫瘍薬
    • エトポシド（トポサール、ベペシド）
    • メトトレキサート（トレキソール）
    • シスプラチン
  • 副腎皮質ステロイド
    • デキサメタゾン（デカドロン、ヘキサドロール）
    • メチルプレドニゾロン
  • 免疫抑制剤
    • シクロスポリン（サンディミュン、ネオーラル）
    • リツキシマブ（リツキサン）
  • 生物製剤
    • エマパルマブ（ガミファント、エマパルマブ-lzsg）
    • アレムツズマブ（キャンパス）
    • タデキニグアルファ
  • 免疫グロブリン

第9章 投与経路別

  • 経口
  • 非経口

第10章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Swedish Orphan Biovitrum
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Incyte
  • Sanofi
  • AB2 Bio Ltd.
  • Genentech, Inc.
  • Pfizer Inc.
  • Viatris Inc.
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • Merck KGaA

第14章 付録

目次
Product Code: PH7162

Overview

The global hemophagocytic lymphohistiocytosis treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Hemophagocytic lymphohistiocytosis (HLH), an uncommon illness, primarily affects babies and young children. The condition typically passes down to children. Adults can develop HLH from a wide range of illnesses, such as cancer and infections.

Government investments and research, particularly in developing economies, will continue to drive utilization of advanced products or technologies and boost the global hemophagocytic lymphohistiocytosis treatment market. The respective innovative products includes the use of novel drugs such as monoclonal antibodies for better treatment.

Market Dynamics: Drivers & Restraints

Growing acquisition and partnerships among key players

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high income levels, investments and infrastructure development. Several countries have experienced substantial demand for Hemophagocytic Lymphohistiocytosis Treatment owing to its positive outcomes in research. Various acquisitions and product launches among key players will be a crucial factor driving the growth of the market.

On March 9, 2023, F-star Therapeutics, Inc., a biopharmaceutical company in the clinical stage that invented bispecific antibodies in immunotherapy, has been successfully acquired by invoX Pharma Limited, a fully-owned subsidiary based in U.K. of Sino Biopharmaceutical Limited ("Sino Biopharm"), for a total approximate cash valuation of $161 million (or $7.12 per share).

According to Canadian Journal of Health Technologies 2022, Anakinra may lower 28-day mortality and the probability of death in people with hemophagocytic lymphohistiocytosis (HLH), according to data from one retrospective cohort research (included in one comprehensive review).

Furthermore, the rising utilization of novel technologies or drugs for the management of hemophagocytic lymphohistIocytosis. Rising awareness among people and increasing research for innovative product development will be a major factor driving the growth of the hemophagocytic lymphohistiocytosis treatments market.

Side effects associated with the medication

High blood pressure, infections, infusion-related adverse responses (fever, redness, rash, sweating), low blood potassium, fever, and constipation are typical side effects. Fever, weakness, coughing, trouble breathing, diarrhea, stomach discomfort, chills, sweating, burning sensations while urinating, and more frequent urination are symptoms of a serious infection. These were the few commonly reported adverse events in the key trial. Gamifant users who experienced less than 10% of these additional graded adverse effects (all grades) included vomiting, acute renal injury, asthenia, dyspnea, bradycardia, gastrointestinal bleeding, epistaxis, and peripheral edema.

For more details on this report - Request for Sample

Segment Analysis

The global hemophagocytic lymphohistiocytosis treatment market is segmented based on type, medication, route of administration, distribution channel and region.

Biologics segment accounted for approximately 38% of market share

Monoclonal antibodies, immune modulators, growth factors, vaccinations, and items made from human blood and plasma all fall within the broad category of biological medicines. Biological treatments have the potential to worsen or possibly start HLH. An interferon gamma (IFN) blocking monoclonal antibody is what Gamifant (emapalumab) is. It reduces inflammation by inhibiting an immune system molecule called interferon gamma. The inflammation-related symptoms of primary HLH are lessened as a result.

On March 7, 2023, the enrollment in the ongoing pivotal Phase 3 research of Tadekinig alfa by AB2 Bio Ltd., a biotechnology business dedicated to discovering novel medicines for the treatment of serious systemic autoinflammatory illnesses and disorders induced by IL-18, has been completed. The goal of the trial is to demonstrate the safety and efficacy of Tadekinig alfa (r-hIL-18BP) for the management of primary monogenic IL-18 led HLH, an extremely rare and fatal illness that primarily affects children and lacks any approved treatments. Topline findings are expected in the second half of 2023, according to AB2 Bio.

Geographical Penetration

North America accounted for around 36% of market share in 2022

Due to the rising need for hemophagocytic lymphohistiocytosis treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for hemophagocytic lymphohistiocytosis treatment.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different type of devices for management, and increase in pharmaceutical or medical device business establishment across the region are also contributing to the growth of hemophagocytic lymphohistiocytosis treatment market share of this region. The market in this area is growing as people become more aware of various novel innovative drugs such as emapalumab. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global hemophagocytic lymphohistiocytosis treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for hemophagocytic lymphohistiocytosis treatment in the U.S. United States have been proactive in executing several initiatives or researches, stimulating hemophagocytic lymphohistiocytosis treatment demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global hemophagocytic lymphohistiocytosis treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various device designs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical device industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for hemophagocytic lymphohistiocytosis treatment. Now several research studies have been initiated and companies have again started trial for their products safety and efficacy. Overall, the impact of the pandemic on the global hemophagocytic lymphohistiocytosis treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for novel therapies, like tadekinig alfa and other programs for management of hemophagocytic lymphohistiocytosis.

Key Developments

  • On January 30, 2023, with the Guangzhou Development Zone Administrative Committee, Sino Biopharm plus its affiliate CTTQ signed a framework agreement to invest in the creation of a regional Southern base and an international innovation hub in the area. By gradually integrating R&D, manufacturing, sales, and marketing services, the Guangzhou invention center will grow to be Sino Biopharm's "second engine" and help the company reach its revenue goal of HK$100 billion by 2030.
  • On December 10, 2022, According to American Society of Hematology, patients in the phase II study got dexamethasone and ruxolitinib (15 mg twice daily) over an eight-week period. Janus kinase (JAK) inhibitor which is orally administered is called roxolitinib inhibits JAK enzymes along with downstream cytokines that are active in HLH, however some JAK-pathway-activated cytokines can lead to glucocorticoid resistance. Ruxolitinib may be able to help reverse this, according to in vitro and in vivo experiments. The medication was well tolerated, according to researchers, and no patients needed dose adjustments.

Competitive Landscape

The major global players in the market include: Swedish Orphan Biovitrum, Incyte, Sanofi, AB2 Bio Ltd., Genentech, Inc., Pfizer Inc., Viatris Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited and Merck KGaA.

Why Purchase the Report?

  • To visualize the global hemophagocytic lymphohistiocytosis treatment market segmentation based on type, medication, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of hemophagocytic lymphohistiocytosis treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global hemophagocytic lymphohistiocytosis treatment market report would provide approximately 69 tables, 67 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Medication
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing acquisition and partnerships among key players
      • 4.1.1.2. Rising technological advancements and developments
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects associated with the medication
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. SWOT Analysis
  • 5.6. Patent Analysis
  • 5.7. Russia-Ukraine War Impact Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Familial Hemophagocytic Lymphohistiocystosis*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Acquired Hemophagocytic Lymphohistiocystosis

8. By Medication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 8.1.2. Market Attractiveness Index, By Medication
  • 8.2. Antineoplastic Agents*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Etoposide (Toposar, VePesid)
    • 8.2.4. Methotrexate (Trexall)
    • 8.2.5. Cisplatin
  • 8.3. Corticosteroids
    • 8.3.1. Dexamethasone (Decadron, Hexadrol)
    • 8.3.2. Methylprednisolone
  • 8.4. Immunosuppressant Agents
    • 8.4.1. Cyclosporine (Sandimmune, Neoral)
    • 8.4.2. Rituximab (Rituxan)
  • 8.5. Biologics
    • 8.5.1. Emapalumab (Gamifant, emapalumab-lzsg)
    • 8.5.2. Alemtuzumab (Campath)
    • 8.5.3. Tadekinig Alfa
  • 8.6. Immune Globulins

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Parenteral

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Swedish Orphan Biovitrum*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Incyte
  • 13.3. Sanofi
  • 13.4. AB2 Bio Ltd.
  • 13.5. Genentech, Inc.
  • 13.6. Pfizer Inc.
  • 13.7. Viatris Inc.
  • 13.8. Bristol-Myers Squibb Company
  • 13.9. Takeda Pharmaceutical Company Limited
  • 13.10. Merck KGaA

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us